Puma Biotechnology starts ALISCA-Lung2 Phase II trial with paclitaxel
Puma Biotechnology initiated its ALISCA®-Lung2 Phase II trial (PUMA-ALI-4202; NCT07465757) testing alisertib with paclitaxel in advanced small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.